{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:35:07Z","timestamp":1791408907465,"version":"4.3.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K99CA277136-01"],"award-info":[{"award-number":["1K99CA277136-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.08.008","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T12:02:27Z","timestamp":1691928147000},"page":"e420-e427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-9777","authenticated-orcid":false,"given":"Hamlet","family":"Gasoyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Doering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham A.","family":"Colditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.008_bib0001","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Myeloma. 2022. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html Accessed March 13, 2022."},{"issue":"2","key":"10.1016\/j.clml.2023.08.008_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2023.08.008_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2023.08.008_bib0004","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.08.008_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/bloodadvances.2017010512","article-title":"Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications","volume":"2","author":"Pulte","year":"2018","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2023.08.008_bib0006","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.clml.2023.08.008_bib0007","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy","author":"Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","volume":"158","author":"Ailawadhi","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.008_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0011","first-page":"39","article-title":"Temporal trends in survival and healthcare costs in patients with multiple myeloma in the United States","volume":"11","author":"Maiese","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clml.2023.08.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.101974","article-title":"Multiple myeloma, race, insurance and treatment","volume":"73","author":"Joshi","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.clml.2023.08.008_bib0013","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clml.2020.04.018","article-title":"Racial disparities in the utilization of novel agents for frontline treatment of multiple myeloma","volume":"20","author":"Fiala","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0014","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2023.08.008_bib0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jnci\/djz243","article-title":"Oral oncology parity laws, medication use, and out-of-pocket spending for patients with blood cancers","volume":"112","author":"Dusetzina","year":"2020","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.clml.2023.08.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15720","article-title":"Association of high-deductible health plan enrollment with spending on and use of lenalidomide therapy among commercially insured patients with multiple myeloma","volume":"5","author":"Jazowski","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2023.08.008_bib0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2023.08.008_sbref0018","series-title":"Study Quality Assessment Tools","year":"2014"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"issue":"28","key":"10.1016\/j.clml.2023.08.008_bib0020","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.2018.77.8894","article-title":"Prescription drug coverage and outcomes of myeloma therapy among Medicare beneficiaries","volume":"36","author":"Olszewski","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.clml.2023.08.008_bib0021","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma","volume":"35","author":"Olszewski","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2023.08.008_bib0022","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.08.008_bib0023","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00277-020-04371-1","article-title":"Utilization of radiation therapy in multiple myeloma: trends and changes in practice","volume":"100","author":"Ailawadhi","year":"2021","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.clml.2023.08.008_bib0024","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.33089","article-title":"Association between race and treatment patterns and survival outcomes in multiple myeloma: a connect MM registry analysis","volume":"126","author":"Ailawadhi","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ajh.23753","article-title":"Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents: trend and disparity in upfront myeloma transplant","volume":"89","author":"Al-Hamadani","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2023.08.008_bib0026","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/COC.0000000000000873","article-title":"Do patients with multiple myeloma enrolled in clinical trials live longer?","volume":"44","author":"Aung","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.08.008_bib0027","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2016.03.008","article-title":"Time to insurance approval in private and public payers does not influence survival in patients who undergo hematopoietic cell transplantation","volume":"22","author":"Bhatt","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2023.08.008_bib0028","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12032-017-1001-7","article-title":"Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort","volume":"34","author":"Chen","year":"2017","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0029","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41375-020-0812-2","article-title":"Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients","volume":"35","author":"Covut","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2023.08.008_bib0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1080\/10428194.2020.1767290","article-title":"Treatment disparities in minority groups with multiple myeloma at a safety-net hospital","volume":"61","author":"Dennis","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2023.08.008_bib0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jgo.2019.06.010","article-title":"Cost differential associated with hospice use among older patients with multiple myeloma","volume":"11","author":"Fiala","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.08.008_bib0033","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2023.08.008_bib0034","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbmt.2015.03.005","article-title":"Re: Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Fiala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.clml.2023.08.008_bib0035","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1080\/10428194.2021.1953012","article-title":"Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States","volume":"62","author":"Fossum","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2023.08.008_bib0036","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.6004\/jnccn.2019.7298","article-title":"Influence of treating facility, provider volume, and patient-sharing on survival of patients with multiple myeloma","volume":"17","author":"Freeman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.clml.2023.08.008_bib0037","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10428190902741471","article-title":"Diagnostic delay and complications for older adults with multiple myeloma","volume":"50","author":"Friese","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.clml.2023.08.008_bib0038","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1002\/cncr.32428","article-title":"Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States","volume":"125","author":"Giri","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.08.008_bib0039","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cam4.2698","article-title":"Utilization of novel systemic therapies for multiple myeloma: a retrospective study of front-line regimens using the SEER-Medicare data","volume":"9","author":"Goto","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.clml.2023.08.008_bib0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.hemonc.2020.09.005","article-title":"Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma","volume":"14","author":"Jayakrishnan","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"10.1016\/j.clml.2023.08.008_bib0041","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.21873\/anticanres.14587","article-title":"Impact of the affordable care act on timeliness to treatment for patients with multiple myeloma","volume":"40","author":"Jayakrishnan","year":"2020","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.clml.2023.08.008_bib0042","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7326\/0003-4819-154-11-201106070-00004","article-title":"Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study","volume":"154","author":"Keating","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.clml.2023.08.008_bib0043","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1200\/JOP.19.00309","article-title":"Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care","volume":"16","author":"Kumar","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2023.08.008_bib0044","doi-asserted-by":"crossref","first-page":"22","DOI":"10.6004\/jnccn.2018.7079","article-title":"Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma","volume":"17","author":"Leng","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0045","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/j.clml.2021.04.006","article-title":"Disparities in utilization of autologous stem cell transplantation as consolidative therapy for multiple myeloma: a single institution retrospective review","volume":"21","author":"Lupak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"10.1016\/j.clml.2023.08.008_bib0046","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/cncr.33831","article-title":"Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0047","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3324\/haematol.2018.187609","article-title":"Meaningful changes in end-of-life care among patients with myeloma","volume":"103","author":"Odejide","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2023.08.008_bib0048","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.clml.2021.02.003","article-title":"Evaluating race and time to transplantation in multiple myeloma: the Mount Sinai hospital experience","volume":"21","author":"Pan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2023.08.008_bib0049","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/COC.0b013e3180592a30","article-title":"Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort","volume":"30","author":"Rohatgi","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2023.08.008_bib0050","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2023.08.008_bib0051","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clml.2019.04.019","article-title":"Superior Survival in African American patients who underwent autologous stem cell transplantation for multiple myeloma","volume":"19","author":"Sweiss","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.clml.2023.08.008_bib0052","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.08.008_bib0053","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1200\/OP.20.00479","article-title":"Racial disparities in intravenous bisphosphonate use among older patients with multiple myeloma enrolled in Medicare","volume":"17","author":"Zhou","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"10.1016\/j.clml.2023.08.008_bib0054","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.clml.2023.08.008_bib0055","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1080\/10428194.2021.1953013","article-title":"Health disparities experienced by black and Hispanic Americans with multiple myeloma in the United States: a population-based study","volume":"62","author":"Al Hadidi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2023.08.008_bib0056","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.clml.2023.08.008_bib0057","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: effect of race and sex","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2023.08.008_bib0058","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/j.clml.2019.05.003","article-title":"A mixed-methods study of stem cell transplantation utilization for newly diagnosed multiple myeloma","volume":"19","author":"Fiala","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.08.008_bib0059","series-title":"Inflation reduction act of 2022","year":"2022"},{"key":"10.1016\/j.clml.2023.08.008_bib0060","unstructured":"US Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials. 2022. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations Accessed April 10, 2023."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:22Z","timestamp":1761871462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002550"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}